Table 1.
Results from the multiple-treatment comparison analyses for mortality (OR [95% Cl]) and GFR (SMD [95% Cl]) in the overall analysis.
| Overall Analysis of Mortality OR (95% CI) | ||||
|---|---|---|---|---|
| Levosimendan | 0.75 (0.57–0.97) * | 0.71 (0.38–1.34) | 0.50 (0.30–0.83) * | 0.62 (0.46–0.84) * |
| 0.18 (−0.19–0.55) | Dobutamine | 0.95 (0.49–1.87) | 0.67 (0.38–1.17) | 0.83 (0.57–1.22) |
| 1.46 (0.88–2.03) | 1.28 (0.59–1.96) | Dopamine | 0.70 (0.35–1.40) | 0.87 (0.50–1.52) |
| - | - | - | Milrinone | 1.25 (0.81–1.91) |
| 1.67 (1.17–2.18) * | 1.49 (0.87–2.12) * | 0.22 (−0.06–0.49) | - | Control |
| Overall analysis of GFR SMD (95% CI) | ||||
Comparisons between treatments should be read from left to right and the estimate is in the cell in common between the column-defining treatment and the row-defining treatment. Mortality is presented as the odds ratio (OR) with 95% confidence interval (CI), while GFR is presented as the standardized mean difference (SMD) with 95% confidence interval (CI). The overall analysis of mortality is shown in the upper right side of the table. The overall GFR analysis is shown in the lower left side of the cells. An OR smaller than 1 favors the row-defined treatment in mortality, and a SMD larger than 0 favors the column-defined treatment in the overall analysis of GFR. * Denotes p-value < 0.05.